Tomahawk, WI 02/04/2014 (BasicsMedia) – Geron Corporation (NASDAQ:GERN) recently developed a new rug called Imetelstat. When Mayo Clinic undertook a study on this drug, it came up with interesting finds, which are likely to boost GERN’s revenues and sales going into 2014, and possibly, beyond. According to Mayo Clinic’s study, this new drug has the capacity to be of great benefit to people affected by bone marrow cancer. From the time when Mayo Clinic published the result of this study, GERN has seen a 17 percent increase in its stock, and better news lie ahead during this quarter.

Mayo decided to put two patients suffering from myelofibrosis to check how they respond to the new drug developed by Geron Corporation (NASDAQ:GERN). The clinic took six months to study all these patients. Amazingly, five of the 22 patients reported a complete remission from myelofibrosis. More than that, Mayo reported that 41 percent of all the patients that took part in this study responded to the Geron drug. Geron provided the funds that Mayo Clinic needed to carry this study and come up with findings to show if the drug was as effective as it hoped or not.

The significance of the results from this study is not lost on anyone who has taken a keen interest in the disease. The number of people who responded to the new drug is almost unheard of for all the previous drugs that were developed to treat this condition. However, both mayo and Geron Corporation (NASDAQ:GERN) say that they cannot make conclusions based on these results, since it is still early days for the new drug. However, the two believe that the drug has thus far shown great promise and has given Geron the impetus it needs to make the drug better and more effective than it has is.

Under myelofibrosis, bone marrow cells produce blood cells, which are unable to function normally. The result is that scar tissues form in the bone marrow causing chronic anemia, which in turn would require the patient to undergo blood transfusion. Other conditions that the disease gives rise to include weakness, and fatigue. Myelofibrosis eventually leads to an enlarged liver and spleen. Therefore, if Imetelstat works as Mayo Clinic’s study found out, this news will have great relevance and Geron in 2014, and please all its shareholders who stand to reap big.

This should be a year of great expectations for Geron Corporation (NASDAQ:GERN), which can do with a couple of good news for its shareholders. While the company is not struggling as much as its peers in the clinical biopharmaceutical sector are, it needs this new drug to work just as effectively as the Mayo Clinic study show. This way, it will succeed in attracting new investors, and raise the capital it needs to reinvest in its operations, or enlarge the parts of its business that has been struggling. No matter what happens, the success of the new drug, thus far, is great news for Geron Corporation.

Geron Corporation (NASDAQ:GERN) has seen its stock rising, and this does not seem to be about to end any time soon, if the positive reviews concerning its new drug keep coming out.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.